A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.
Salah-Eddin Al-Batran(Goethe University Frankfurt), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Georg Martin Haag(Heidelberg University), Vera Heuer(St. Anna Hospital), Christina Kopp(Krankenhaus Nordwest), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Jorge Riera‐Knorrenschild, Thomas J. Ettrich(Universität Ulm), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Udo Lindig(Jena University Hospital), Stefan Angermeier(Klinikum Ludwigsburg), Michael Schenk(Krankenhaus Barmherzige Brüder), Albrecht Kretzschmar(Roche (Switzerland)), Sylvie Lorenzen(Technical University of Munich), Alexander Siebenhuener(University Hospital Zurich), Claudia Pauligk(Goethe University Frankfurt)
Cited by 13
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k